Home
overview
As the incidence of asthma increases world-wide it is definitely becoming a serious public health threat, especially within pediatrics and the urban environment. Inhaled corticosteroids have a major role in asthma management, however there are concerns about the long-term use of some agents, particularly at high doses.

This unique conference will explore the development of new therapies against asthma and how management programmes are making a difference to the patients. It will be informative, stimulating and focused.

The conference offers you the opportunity to network with key industry experts. Attend to discover the potential and realities of the asthma market, and to match your company’s resources to the needs of the consumer.

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Peter J Barnes

Peter J Barnes, Professor of Thoracic Medicine, Imperial College School of Medicine at the National Heart and Lung Institute

9:10 UNMET NEEDS IN ASTHMA HEALTH MANAGEMENT

Dr George Fulop

Dr George Fulop, Director, Medical Policy and Programs, Merck-Medco Managed Care

  • Health management programs for patients
  • The importance of education and empowerment in asthma care
  • Using patient education to improve usage of asthma medication especially controller medications
  • Anticipated outcomes from disease management programs
  • Targeting a range of sufferers: mild to severe disease conditions
  • Improved and full compliance with asthma medication regimes
  • 9:40 MANAGING ASTHMA TREATMENT

    Dr Kulasiri A Gunawardena

    Dr Kulasiri A Gunawardena, Director Clinical Research, Chiltern International

  • Disease management in the context of the natural history of asthma
  • The ideal therapeutic agent
  • Current treatment options and their shortcomings
  • Pharamcoeconomic trends
  • Consumer empowerment and self management
  • Education and benefits of self management programmes
  • 10:20 CURRENT AND FUTURE TREATMENT STRATEGIES

    Dr Steve Webber

    Dr Steve Webber, Therapeutic Area Head for Asthma/Inflammation, Rhone Poulenc Rorer

  • Action plans for development of new therapeutics
  • Current recommendations for management of asthma symptoms
  • Short-acting b2-agonists for symptomatic treatment
    Earlier use of long-acting b2-agonists
  • Corticosteroids and other anti inflammatories
  • Future targets of significant interest
  • Where do the opportunities for improvement lie?
  • 11:00 Morning Coffee

    11:20 MOLECULAR THERAPEUTICS FOR RESPIRATORY DISEASES

    Dr Jonathan W Nyce

    Dr Jonathan W Nyce, Chief Scientific Officer, EpiGenesis Pharmaceuticals

  • Respirable antisense oligonucleotide technology (RASON) : oligonucleotide-based target validation in the hyper responsive airway
  • Modelling human asthma to improve the ability to predict drug efficacy in man
  • Clinical candidates for asthma:
  • EPI 2010 - targeting adenosine receptors. Potential to be weekly asthma treatment
  • EPI 12322 - non glucocorticoid steroid
  • Building a proprietary pipeline of clinical candidates for asthma and other respiratory diseases
  • 12:00 GENETIC FACTORS IN THE PATHOGENESIS OF ASTHMA

    Dr Roy Clifford Levitt

    Dr Roy Clifford Levitt, Chief Operating Officer, Magainin

  • Validating the role of the IL-9 pathway in asthma
  • Role of IL-9 stimulation of cell types mediating the disease state
  • The importance of funtional genomics in target discovery
  • Identification and validation of novel small molecule targets for treatment
  • Functional high throughput screen development
    High throughput in vivo model systems
  • Therapeutic development strategies for IL-9 pathway antagonists
  • 12:40 Lunch

    14:00 NEW ORAL TREATMENTS FOR ASTHMA

    Dr John Montana

    Dr John Montana, Director, Drug Discovery, Chiroscience

  • Asthma characterised by invasion of the airways by inflammatory cells (eosinophils) and bronchoconstriction
  • Development of orally active anti-inflammatory drugs inhibiting PDE IV
  • PDE IV inhibitors possess anti-inflammatory potential
  • Modulating potential emetic side effects - D4418
  • Encouraging results in pre-clinical models of asthma
  • Developing lead compounds to deliver a viable treatment for asthma
  • 14:40 MEDICAL MARKETING OF ASTHMA DRUGS

    Dr Lothar Boesch

    Dr Lothar Boesch, Marketing Director, Byk Gulden

  • Epidemiology and future market implications
  • Customer profiles, needs and demands
  • Inhaled corticosteroids, strengths and pittfalls
  • Ciclesonide – new approach in steroid therapy
  • Breaking new ground in anti inflammatory therapy with PDE inhibitors
  • Roflumilast – new generation compound for asthma treatment
  • 15:20 Afternoon Tea

    15:40 CELLULAR AND MOLECULAR TARGETS IN ASTHMA

    Dr Michel Pairet

    Dr Michel Pairet, Head, Pulmonary Research, Boehringer Ingelheim

  • Defining cellular / molecular targets according to therapeutic goals
  • Bronchodilation / anti-inflammatory activity / targeting tissue remodelling
  • Orally active leukotrienes LTB4 antagonist / tryptase inhibitors
  • The place of genomics in drug discovery programmes
  • New drug delivery technologies
  • 16:20 TO BE ANNOUNCED

    17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and coffee

    9:00 Chairman's Opening Remarks

    Prof Fan Chung

    Prof Fan Chung, Professor of Respiratory Medicine, Imperial College School of Medicine at the National Heart and Lung Institute

    9:10 DELIVERY SYSTEMS FOR ASTHMA DRUGS

    Dr David Byron

    Dr David Byron, Executive Vice President, Scientific Affairs, Sheffield Pharmaceuticals

  • The importance of specific drug delivery systems for asthma
  • Strategic development of new devices: partnerships to advance worldwide development programmes
  • Taking a new device into clinical development: examining the efficacy and safety of the MSI delivery system
  • Expansion of initial trials to cover a wider market: pediatrics and other indications
  • The future markets for inhalers – competitions with oral formulation
  • 9:40 ENGINEERING AN ASTHMA PRODUCT

    Dr Mark Parry-Billings

    Dr Mark Parry-Billings, Director, Research and Development, INNOVATA Biomed, the Respiratory Division of ML Laboratories

  • Review of the wide range of delivery devices available
  • Technical influences on the choice of delivery device
  • Selecting a device development partner
  • Clickhaler: experiences of deleloping and registering a novel delivery technology
  • 10:20 GETTING THE INHALED DRUG FROM THE DEVICE TO THE PATIENT: WHY THE DILEMMA?

    Dr Robert K Schultz

    Dr Robert K Schultz, Vice President, Product Development, DURA Pharmaceuticals

  • Reviewing the current device performance and drug delivery efficiencies
  • Explaining the consequences to product and clinical development when the inhaler/patient interface is not well controlled
  • Exploring potential opportunities and benefits associated with improving inhalation delivery efficiency and effectiveness
  • Discussing an inhaler technology that improves the patient/inhaler interface: Spiros a novel dry powder inhalation system
  • 11:00 Morning Coffee

    11:20 THE UNMET MEDICAL NEED

    Dr Emmett Clemente

    Dr Emmett Clemente, Chairman and Founder, Ascent Pediatrics

  • Providing branded pharmaceuticals to the pediatric market
  • Developing new products based on approved compounds to more benefit the pediatric market
  • Taste - important factor for compliance in the pediatric market
  • Orapred - improved tasting formulation
  • Strategies for developing branded compounds for pediatric applications
  • Strategies in gaining approval for pediatric applications
  • 12:00 TRYPTASE

    Dr Sarah Lively

    Dr Sarah Lively, Project Leader, Proteus International

  • Tryptase as a mediator in allergic diseases
  • Application of CAMD to serine protease targets
  • Profile of novel series of tryptase inhibitors
  • Lead optimisation and target profile attributes
  • 12:40 Lunch

    14:00 PHARMACOGENETICS OF ASTHMA

    Dr Krishnan Nanabalan

    Dr Krishnan Nanabalan, Executive Director, Technology Systemes, Gennaissance Pharmaceuticals

  • Albuterol has a broad response among humans
  • ß-adrenergic receptor (ß-AR) has substantial genetic variation
  • ß-AR haplotypes as predictors of responsiveness to ß-agonist
  • Correlation of ß-AR haplotype markers with albuterol response
  • Haplotypes as useful clinical predictors in early human testing
  • 14:40 HUMANISED ANTIBODIES FOR ASTHMA

    Dr Nancy T. Chang

    Dr Nancy T. Chang, President and CEO, Tanox

  • Identifying key components within disease pathways that result in pathological conditions
  • Straightforward research strategy - understand the biology and generate effective drug targeting that component
  • Generation of novel monoclonal antibodies and genetic manipulation of antibody-based products to make them optimal for use in man
  • Strategies for product development - partnering or retaining control
  • Discovery research and development of the product pipeline
  • 15:20 Afternoon Tea

    15:40 TREATMENT OF ALLERGIES, ASTHMA AND RESPIRATORY DISEASES

    Dr John Langlands

    Dr John Langlands, Vice President, Preclinical Product Development, Inflazyme

  • Development of natural compounds - IPL 576
  • Comparative efficacy to inhaled glucocorticoids without associated side effects
  • Completing preclinical toxicology and moving towards clinical trials
  • Determination of mode of action: Potential for further novel product development
  • Working towards commercialisation of drugs to treat serious inflammatory therapies
  • 16:20 TO BE ANNOUNCED

    17:00 Chairman's Closing Remarks and Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.